SkyePharma plc, of London, appointed Frank Condella to its board.

StressGen Biotechnologies Corp., of San Diego, appointed Robert Rieder to its board and Jay Short chairman.

Syngenta, of Basel, Switzerland, appointed Carsten Tilger head of communication and public affairs.

Telik Inc., of Palo Alto, Calif., appointed Michael Inouye senior vice president, commercial operations.

The Avicena Group Inc., of Palo Alto, Calif., appointed Michael Sullivan vice president of finance and acting chief financial officer.

Threshold Pharmaceuticals Inc., of Redwood City, Calif., appointed Michael Brawer urology therapeutic area head.

Topigen Pharmaceuticals Inc., of Montreal, appointed Mitchell Glass to its scientific advisory board.

Tracon Pharmaceuticals Inc., of San Diego, appointed Bryan Leigh chief medical officer, Mazen Skaf chief business officer, Elizabeth Clark Moore vice president of regulatory affairs, and Kim Weinberger head of clinical operations.

Transgenomic Inc., of Omaha, Neb., appointed Michael Summers interim CEO.

Upstream Biosciences Inc., of Vancouver, British Columbia, appointed Wyeth Wasserman to its scientific advisory board.

VaxGen Inc., of Brisbane, Calif., appointed Matthew Pfeffer chief financial officer and senior vice president of finance and administration.

Ventaira Pharmaceuticals, of Columbus, Ohio, appointed Phyllis Gardner to its board.

VioQuest Pharmaceuticals Inc., of Basking Ridge, N.J., appointed Pamela Harris chief medical officer.

Vitae Pharmaceuticals Inc., of Fort Washington, Pa., appointed Donald Hayden chairman.

Xention Discovery Ltd., of Cambridge, UK, appointed Kenneth Cunningham and Wolfgang Hartwig nonexecutive directors.

ZymoGenetics Inc., of Seattle, appointed Judith Hemberger to its board.